Zlatopolskiy Boris D, Zischler Johannes, Urusova Elizaveta A, Endepols Heike, Kordys Elena, Frauendorf Holm, Mottaghy Felix M, Neumaier Bernd
Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany.
Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany ; Clinic of Nuclear Medicine, RWTH Aachen University Pauwelsstraße 30, 52074, Aachen, Germany.
ChemistryOpen. 2015 Aug;4(4):457-62. doi: 10.1002/open.201500056. Epub 2015 May 7.
Recently a novel method for the preparation of (18)F-labeled arenes via oxidative [(18)F]fluorination of easily accessible and sufficiently stable nickel complexes with [(18)F]fluoride under exceptionally mild reaction conditions was published. The suitability of this procedure for the routine preparation of clinically relevant positron emission tomography (PET) tracers, 6-[(18)F]fluorodopamine (6-[(18)F]FDA), 6-[(18)F]fluoro-l-DOPA (6-[(18)F]FDOPA) and 6-[(18)F]fluoro-m-tyrosine (6-[(18)F]FMT), was evaluated. The originally published base-free method was inoperative. However, a "low base" protocol afforded protected radiolabeled intermediates in radiochemical conversions (RCCs) of 5-18 %. The subsequent deprotection step proceeded almost quantitatively (>95 %). The simple one-pot two-step procedure allowed the preparation of clinical doses of 6-[(18)F]FDA and 6-[(18)F]FDOPA within 50 min (12 and 7 % radiochemical yield, respectively). In an unilateral rat model of Parkinsons disease, 6-[(18)F]FDOPA with high specific activity (175 GBq μmol(-1)) prepared using the described nickel-mediated radiofluorination was compared to 6-[(18)F]FDOPA with low specific activity (30 MBq μmol(-1)) produced via conventional electrophilic radiofluorination. Unexpectedly both tracer variants displayed very similar in vivo properties with respect to signal-to-noise ratio and brain distribution, and consequently, the quality of the obtained PET images was almost identical.
最近,一篇论文报道了一种全新的方法,可在极为温和的反应条件下,通过用[¹⁸F]氟化物对易于获取且足够稳定的镍配合物进行氧化[¹⁸F]氟化反应来制备[¹⁸F]标记的芳烃。该方法用于常规制备临床相关的正电子发射断层扫描(PET)示踪剂,如6-[¹⁸F]氟多巴胺(6-[¹⁸F]FDA)、6-[¹⁸F]氟-L-多巴(6-[¹⁸F]FDOPA)和6-[¹⁸F]氟间酪氨酸(6-[¹⁸F]FMT)的适用性得到了评估。最初发表的无碱方法无法实施。然而,一种“低碱”方案在5 - 18%的放射化学转化率(RCCs)下提供了受保护的放射性标记中间体。随后的脱保护步骤几乎定量进行(>95%)。这种简单的一锅两步法能够在50分钟内制备出临床剂量的6-[¹⁸F]FDA和6-[¹⁸F]FDOPA(放射化学产率分别为12%和7%)。在帕金森病单侧大鼠模型中,将使用所述镍介导的放射性氟化反应制备的高比活度(175 GBq μmol⁻¹)的6-[¹⁸F]FDOPA与通过传统亲电放射性氟化反应产生的低比活度(30 MBq μmol⁻¹)的6-[¹⁸F]FDOPA进行了比较。出乎意料的是,两种示踪剂变体在信噪比和脑部分布方面显示出非常相似的体内特性,因此,所获得的PET图像质量几乎相同。